These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11317010)

  • 1. A new CX3 CR1 genotype with implications for HIV disease progression.
    Roman F; Deroo S; Franck N; Burgy C; Servais J; Schmit JC
    AIDS; 2001 Mar; 15(5):659-60. PubMed ID: 11317010
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic polymorphism in CX3CR1 and risk of HIV disease.
    McDermott DH; Colla JS; Kleeberger CA; Plankey M; Rosenberg PS; Smith ED; Zimmerman PA; Combadière C; Leitman SF; Kaslow RA; Goedert JJ; Berger EA; O'Brien TR; Murphy PM
    Science; 2000 Dec; 290(5499):2031. PubMed ID: 11187812
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1.
    Faure S; Meyer L; Costagliola D; Vaneensberghe C; Genin E; Autran B; Delfraissy JF; McDermott DH; Murphy PM; Debré P; Théodorou I; Combadière C
    Science; 2000 Mar; 287(5461):2274-7. PubMed ID: 10731151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes.
    Rappaport J; Cho YY; Hendel H; Schwartz EJ; Schachter F; Zagury JF
    Lancet; 1997 Mar; 349(9056):922-3. PubMed ID: 9093257
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.
    Huang Y; Paxton WA; Wolinsky SM; Neumann AU; Zhang L; He T; Kang S; Ceradini D; Jin Z; Yazdanbakhsh K; Kunstman K; Erickson D; Dragon E; Landau NR; Phair J; Ho DD; Koup RA
    Nat Med; 1996 Nov; 2(11):1240-3. PubMed ID: 8898752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of genetic case-control studies in AIDS and application to the CX3CR1 polymorphism.
    Hendel H; Winkler C; An P; Roemer-Binns E; Nelson G; Haumont P; O'Brien S; Khalilli K; Zagury D; Rappaport J; Zagury JF
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):507-11. PubMed ID: 11391174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDS research. Receptor mutations help slow disease progression.
    Cohen J
    Science; 1996 Sep; 273(5283):1797-8. PubMed ID: 8815542
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV-1 infection in an individual homozygous for the CCR5 deletion allele.
    Biti R; Ffrench R; Young J; Bennetts B; Stewart G; Liang T
    Nat Med; 1997 Mar; 3(3):252-3. PubMed ID: 9055842
    [No Abstract]   [Full Text] [Related]  

  • 9. CCR5-delta 32 gene deletion in HIV-1 infected patients.
    Wang B; Palasanthiran P; Zeigler J; Cunningham A; Saksena NK
    Lancet; 1997 Sep; 350(9079):742. PubMed ID: 9291932
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV-1-resistant individuals may lack HIV-1 coreceptor.
    Bradbury J
    Lancet; 1996 Aug; 348(9025):463. PubMed ID: 8709791
    [No Abstract]   [Full Text] [Related]  

  • 11. Resistance to HIV-1 infection: it's in the genes.
    Fauci AS
    Nat Med; 1996 Sep; 2(9):966-7. PubMed ID: 8782446
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV-1 infection in a man homozygous for CCR5 delta 32.
    O'Brien TR; Winkler C; Dean M; Nelson JA; Carrington M; Michael NL; White GC
    Lancet; 1997 Apr; 349(9060):1219. PubMed ID: 9130945
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of CCR2 and CCR5 variants on HIV disease: abstract and commentary.
    Collman RG
    JAMA; 1997 Dec; 278(23):2113-4. PubMed ID: 9403430
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group.
    Theodorou I; Meyer L; Magierowska M; Katlama C; Rouzioux C
    Lancet; 1997 Apr; 349(9060):1219-20. PubMed ID: 9130946
    [No Abstract]   [Full Text] [Related]  

  • 15. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group.
    Meyer L; Magierowska M; Hubert JB; Rouzioux C; Deveau C; Sanson F; Debre P; Delfraissy JF; Theodorou I
    AIDS; 1997 Sep; 11(11):F73-8. PubMed ID: 9302436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural resistance to HIV?
    Hill CM; Littman DR
    Nature; 1996 Aug; 382(6593):668-9. PubMed ID: 8751431
    [No Abstract]   [Full Text] [Related]  

  • 17. [Variant genotyping of CCR2-64I, SDF1-3' A and CCR5Delta32 in HIV-1 infected Chinese long-term nonprogressors].
    Wang SX; Shang H; Han XX; Zhang ZN; Wang YN; Zhang M; Jiang YJ; Liu J; Su YL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):16-9. PubMed ID: 16642210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CC-chemokine receptor 5 genotypes and in vitro susceptibility to HIV-1 of a cohort of British HIV-exposed uninfected homosexual men.
    Aarons E; Fernandez M; Rees A; McClure M; Weber J
    AIDS; 1997 Apr; 11(5):688-9. PubMed ID: 9108955
    [No Abstract]   [Full Text] [Related]  

  • 19. Host genes and HIV infection: implications and applications.
    Kaslow RA
    Emerg Infect Dis; 1997; 3(3):401-2. PubMed ID: 9284391
    [No Abstract]   [Full Text] [Related]  

  • 20. Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele.
    McNicholl JM; Smith DK; Qari SH; Hodge T
    Emerg Infect Dis; 1997; 3(3):261-71. PubMed ID: 9284370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.